{
    "id": 1324,
    "name": "lung cancer",
    "source": "DOID",
    "definition": "A respiratory system cancer that is located_in the lung. [url:http\\://en.wikipedia.org/wiki/Lung_cancer]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "13075",
        "9881",
        "1322"
    ],
    "termId": "DOID:1324",
    "evidence": [
        {
            "id": 11,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed lung epithelial cells expressing ARAF S214C in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 359,
                "profileName": "ARAF S214C"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 189,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I clinical trials, increased expression of Nf1 conferred resistance to Tarceva (erlotinib) in lung adenocarcinoma patients (PMID: 24535670).",
            "molecularProfile": {
                "id": 595,
                "profileName": "NF1 dec exp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 268,
                    "pubMedId": 24535670,
                    "title": "Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24535670"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 305,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial of patients with advanced NSCLC, the combination of Cediranib (AZD-2171) and carboplatin/paclitaxel (CP) chemotherapy resulted in improved response rate over placebo plus CP, but did not improve progression-free survival, and the study did not proceed to Phase III due to toxicity (PMID: 24360368).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1664,
                "therapyName": "Carboplatin + Cediranib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 95,
                    "pubMedId": 24360368,
                    "title": "Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24360368"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 308,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rociletinib (CO-1686) induced tumor regression in EGFR-mutant human non-small cell lung cancer cell line xenograft models, while slightly inhibiting tumor growth in xenograft models of a wild-type EGFR human squamous carcinoma cell line (PMID: 24065731).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 157,
                    "pubMedId": 24065731,
                    "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24065731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 314,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-101 inhibited the growth of lung cancer cells expressing EGFR T790M (PMID: 20388807).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 1005,
                "therapyName": "CUDC-101",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 43,
                    "pubMedId": 20388807,
                    "title": "CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20388807"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 427,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-mutant non-small-cell lung cancer (PMID: 24323026).",
            "molecularProfile": {
                "id": 1216,
                "profileName": "ERBB2 mutant"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 94,
                    "pubMedId": 24323026,
                    "title": "Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24323026"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 431,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nintedanib, alone or with chemotherapy, inhibited tumor growth in cell line xenograft models of lung and pancreatic cancer but not in cell culture (PMID:23729403).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 81,
                    "pubMedId": 23729403,
                    "title": "BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729403"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1264,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Notch3 signaling through the gamma-secretase inhibitor, MRK-003, blocked tumor growth and prolonged survival in mouse xenograft models of lung cancer (PMID: 17804716).",
            "molecularProfile": {
                "id": 600,
                "profileName": "NOTCH3 wild-type"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 979,
                    "pubMedId": 17804716,
                    "title": "Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17804716"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1288,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 reduced tumor size in mouse models of lung cancer carrying PIK3CA H1047R (PMID: 19029981).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1289,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sirolimus (rapamycin) did not induce tumor shrinkage in mouse lung cancer models carrying PIK3CA H1047R (PMID: 19029981).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1290,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 did not induce tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1291,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 in combination with Selumetinib (AZD6244) induced tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1389,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) reduced MEK pathway activation and promoted apoptosis of lung cancer cells harboring KRAS G12C and FGFR4 P712T mutations in culture (PMID: 23836671).",
            "molecularProfile": {
                "id": 18651,
                "profileName": "FGFR4 P712T KRAS G12C"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1133,
                    "pubMedId": 23836671,
                    "title": "Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836671"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1468,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, GPR32 mediated part of the suppressive effect of resolvin D1, an endogenous anti-inflammatory, on TGF-beta-induced epithelial-mesenchymal-transition in lung cancer cells (PMID: 24120851).",
            "molecularProfile": {
                "id": 2567,
                "profileName": "GPR32 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1319,
                    "pubMedId": 24120851,
                    "title": "Resolvin D1 inhibits TGF-\u03b21-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24120851"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1520,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In preclinical studies, a chalcone derivative, Chal-24, demonstrated anticancer activity in a lung cancer xenograft (PMID: 19883086) and was shown to act through induction of autophagy via JNK pathways (MAPK8 and MAPK9), resulting in necroptosis in lung cancer cell lines (PMID: 23831571).",
            "molecularProfile": {
                "id": 2618,
                "profileName": "MAPK8 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1446,
                    "pubMedId": 19883086,
                    "title": "Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19883086"
                },
                {
                    "id": 1447,
                    "pubMedId": 23831571,
                    "title": "A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23831571"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1523,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In preclinical studies, a chalcone derivative, Chal-24, demonstrated anticancer activity in a lung cancer xenograft (PMID: 19883086) and was shown to act through induction of autophagy via JNK pathways (MAPK8 and MAPK9), resulting in necroptosis in lung cancer cell lines (PMID: 23831571).",
            "molecularProfile": {
                "id": 2619,
                "profileName": "MAPK9 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1446,
                    "pubMedId": 19883086,
                    "title": "Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19883086"
                },
                {
                    "id": 1447,
                    "pubMedId": 23831571,
                    "title": "A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23831571"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1555,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In preclinical studies, the microRNA MiR-365 was demonstrated to negatively regulate NKX2-1, suggesting it could be a target for lung cancer therapy (PMID: 23507558, PMID: 22185756).",
            "molecularProfile": {
                "id": 2676,
                "profileName": "NKX2-1 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1513,
                    "pubMedId": 23507558,
                    "title": "MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23507558"
                },
                {
                    "id": 1514,
                    "pubMedId": 22185756,
                    "title": "MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22185756"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1586,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "Preclinical shRNA mediated-inhibition of PIWIL1 in xenograft models of lung cancer resulted in decreased tumor growth, suggesting that PIWIL1 may be a promising therapeutic target (PMID: 23621188).",
            "molecularProfile": {
                "id": 2706,
                "profileName": "PIWIL1 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1582,
                    "pubMedId": 23621188,
                    "title": "Hiwi knockdown inhibits the growth of lung cancer in nude mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23621188"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2174,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 S259A demonstrated sensitivity to Nexavar (sorafenib) resulting in decreased phosphorylation of MEK in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 1158,
                "profileName": "RAF1 S259A"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2175,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 S259A demonstrated sensitivity to Mekinist (trametinib) resulting in decreased phosphorylation of Erk in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 1158,
                "profileName": "RAF1 S259A"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2176,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 S257L demonstrated sensitivity to Nexavar (sorafenib) resulting in reduced phosphorylation of MEK in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 1262,
                "profileName": "RAF1 S257L"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2177,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 S257L demonstrated sensitivity to Mekinist (trametinib) resulting in decreased phosphorylation of Erk in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 1262,
                "profileName": "RAF1 S257L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2220,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Bufalin reduced Ncoa3 protein levels and inhibited proliferation of lung cancer cells in culture (PMID: 24390736).",
            "molecularProfile": {
                "id": 6301,
                "profileName": "NCOA3 over exp"
            },
            "therapy": {
                "id": 1862,
                "therapyName": "Bufalin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1489,
                    "pubMedId": 24390736,
                    "title": "Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24390736"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed lung epithelial cells expressing ARAF S214F in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 1129,
                "profileName": "ARAF S214F"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2326,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed lung epithelial cells expressing ARAF S214T in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 1130,
                "profileName": "ARAF S214T"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2467,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human lung cancer cell line over expressing EHMT2 was sensitive to BIX-01294 as demonstrated by suppression of cell growth (PMID: 21847359).",
            "molecularProfile": {
                "id": 8035,
                "profileName": "EHMT2 over exp"
            },
            "therapy": {
                "id": 2862,
                "therapyName": "BIX-01294",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3123,
                    "pubMedId": 21847359,
                    "title": "Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21847359"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2565,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the monoclonal antibody, 11C12 sensitized human lung cancer cell lines with EphA5 over expression to ionizing radiation in culture and in xenograft models (PMID: 25623065).",
            "molecularProfile": {
                "id": 9431,
                "profileName": "EPHA5 over exp"
            },
            "therapy": {
                "id": 4507,
                "therapyName": "11C12 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3290,
                    "pubMedId": 25623065,
                    "title": "Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25623065"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8294,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 5339,
                "profileName": "EML4 - ALK ALK G1202R"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2649,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315).",
            "molecularProfile": {
                "id": 5339,
                "profileName": "EML4 - ALK ALK G1202R"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3367,
                    "pubMedId": 26144315,
                    "title": "PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26144315"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3541,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of lung cancer cells with FGFR1 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 996,
                "therapyName": "Brivanib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3700,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Cediranib and Iressa (gefitinib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with lung cancer (PMID: 20061136).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3229,
                "therapyName": "Cediranib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3999,
                    "pubMedId": 20061136,
                    "title": "Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20061136"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4435,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LQZ-7F treatment in lung cancer cells expressing Birc5 resulted in decreased cell survival in culture (PMID: 26744521).",
            "molecularProfile": {
                "id": 18137,
                "profileName": "BIRC5 positive"
            },
            "therapy": {
                "id": 3506,
                "therapyName": "LQZ-7F",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4545,
                    "pubMedId": 26744521,
                    "title": "Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4618,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SH-1242 inhibited lung tumor growth in a KRAS G12D-expressing transgenic mouse model that forms spontaneous lung tumors (PMID: 26645561).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3552,
                "therapyName": "SH-1242",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4627,
                    "pubMedId": 26645561,
                    "title": "Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4657,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the TTK (MPS1) inhibitor, SNG12, inhibited proliferation of lung cancer cells in culture and suppressed tumor growth in cell line xenograft models (PMID: 24900510).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3593,
                "therapyName": "SNG12",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4666,
                    "pubMedId": 24900510,
                    "title": "Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24900510"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4888,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 treatment inhibited mTOR signaling and cell viability in lung cancer cell lines harboring RICTOR amplification and PDGFRA amplification in culture (PMID: 26370156)",
            "molecularProfile": {
                "id": 19448,
                "profileName": "PDGFRA amp RICTOR amp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4889,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) treatment inhibited mTOR signaling and cell viability in lung cancer cell lines harboring RICTOR amplification and PDGFRA amplification in culture (PMID: 26370156).",
            "molecularProfile": {
                "id": 19448,
                "profileName": "PDGFRA amp RICTOR amp"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4890,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) treatment inhibited mTORC1 signaling and cell viability in lung cancer cell lines harboring RICTOR amplification and PDGFRA amplification in culture (PMID: 26370156)",
            "molecularProfile": {
                "id": 19448,
                "profileName": "PDGFRA amp RICTOR amp"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5224,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells treated with TAK-960 demonstrated a decrease in tumor size in cell line xenograft models (PMID: 22188812).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3780,
                "therapyName": "TAK-960",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4929,
                    "pubMedId": 22188812,
                    "title": "TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22188812"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5409,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).",
            "molecularProfile": {
                "id": 20862,
                "profileName": "KRAS G12D STK11 inact mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5053,
                    "pubMedId": 26574479,
                    "title": "Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26574479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5517,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-970 sensitized patient-derived lung cancer cells to cisplatin in culture and in PDX models (PMID: 25010037).",
            "molecularProfile": {
                "id": 20962,
                "profileName": "ATR positive"
            },
            "therapy": {
                "id": 3109,
                "therapyName": "Cisplatin + VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5082,
                    "pubMedId": 25010037,
                    "title": "Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25010037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5592,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KJ-Pyr-9 inhibited proliferation of lung cancer cells harboring increased Myc activity in culture (PMID: 25114221).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3903,
                "therapyName": "KJ-Pyr-9",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5115,
                    "pubMedId": 25114221,
                    "title": "Inhibitor of MYC identified in a Kr\u00f6hnke pyridine library.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25114221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5597,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127).",
            "molecularProfile": {
                "id": 1882,
                "profileName": "STK11 loss"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5119,
                    "pubMedId": 26833127,
                    "title": "STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26833127"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",
            "molecularProfile": {
                "id": 21947,
                "profileName": "EML4 - ALK SRC pos"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5176,
                    "pubMedId": null,
                    "title": "The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",
            "molecularProfile": {
                "id": 21947,
                "profileName": "EML4 - ALK SRC pos"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5176,
                    "pubMedId": null,
                    "title": "The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5837,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OTS167 altered the morphology of MELK over-expressing lung cancer cells in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26918358).",
            "molecularProfile": {
                "id": 21948,
                "profileName": "MELK over exp"
            },
            "therapy": {
                "id": 3951,
                "therapyName": "OTS167",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5177,
                    "pubMedId": 26918358,
                    "title": "Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26918358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6055,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HD105 inhibited tumor progression in human lung cancer cell line xenograft models (PMID: 27049350).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4011,
                "therapyName": "HD105",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5258,
                    "pubMedId": 27049350,
                    "title": "Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27049350"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6116,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells treated with VX-970 resulted in a synthetic lethal effect when combined with AZD7762, demonstrating increased survival and decreased tumor volume in xenograft models (PMID: 26748709).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4057,
                "therapyName": "AZD7762 + VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5316,
                    "pubMedId": 26748709,
                    "title": "Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26748709"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6160,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human lung cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 4070,
                "therapyName": "Crizotinib + Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6450,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Mekinist (trametinib) in culture (PMID: 26582713).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6451,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Refametinib (BAY86-9766) in culture (PMID: 26582713).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6452,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring KRAS G12S demonstrated a decreased response when treated with PD-0325901 in culture (PMID: 26582713).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5602,
                    "pubMedId": 26582713,
                    "title": "Identification of an \"Exceptional Responder\" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582713"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6568,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GZD856 inhibited proliferation and induced cell-cycle arrest in lung cancer cells with PDGFRA amplification that lacked expression of PDGFRB, and inhibited tumor growth in xenograft models (PMID: 26940138).",
            "molecularProfile": {
                "id": 23624,
                "profileName": "PDGFRA amp PDGFRB neg"
            },
            "therapy": {
                "id": 4149,
                "therapyName": "GZD856",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5695,
                    "pubMedId": 26940138,
                    "title": "GZD856, a novel potent PDGFR\u03b1/\u03b2 inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26940138"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6572,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GZD856 demonstrated limited efficacy in a PDGFRA-negative lung cancer cell line that expressed PDGFRB in culture, however, it inhibited tumor growth and metastasis in PDGFRA-negative, PDGFRB-positive lung cancer cell line xenograft models (PMID: 26940138).",
            "molecularProfile": {
                "id": 23629,
                "profileName": "PDGFRA neg PDGFRB pos"
            },
            "therapy": {
                "id": 4149,
                "therapyName": "GZD856",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5695,
                    "pubMedId": 26940138,
                    "title": "GZD856, a novel potent PDGFR\u03b1/\u03b2 inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26940138"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6587,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABTL0812 inhibited growth and mTORC1 signaling and induced autophagy in a human lung cancer cell line in culture (PMID: 26671995).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2151,
                "therapyName": "ABTL0812",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5093,
                    "pubMedId": 26671995,
                    "title": "The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26671995"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6791,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited proliferation of lung cancer cell lines harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5821,
                    "pubMedId": 23082000,
                    "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23082000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6867,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000).",
            "molecularProfile": {
                "id": 542,
                "profileName": "FGFR1 wild-type"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5821,
                    "pubMedId": 23082000,
                    "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23082000"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6956,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 3148,
                "profileName": "ERBB2 Y772_A775dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6957,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24125,
                "profileName": "ERBB2 G776delinsVC"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6958,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24128,
                "profileName": "ERBB2 G776delinsLC"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6959,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 3278,
                "profileName": "ERBB2 G778_P780dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6963,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 3148,
                "profileName": "ERBB2 Y772_A775dup"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6965,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24125,
                "profileName": "ERBB2 G776delinsVC"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6966,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24128,
                "profileName": "ERBB2 G776delinsLC"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6967,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 3278,
                "profileName": "ERBB2 G778_P780dup"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6969,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) V659E did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 11379,
                "profileName": "ERBB2 V659E"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6970,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells cells expressing ERBB2 (HER2) G660D did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24165,
                "profileName": "ERBB2 G660D"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6971,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) V659E in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 11379,
                "profileName": "ERBB2 V659E"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14509,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in partial response in the lung lesion and stable bone metastasis for over 16 months in a patient with familial lung cancer harboring germline ERBB2 G660D mutation (PMID: 29146616).",
            "molecularProfile": {
                "id": 24165,
                "profileName": "ERBB2 G660D"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11692,
                    "pubMedId": 29146616,
                    "title": "Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29146616"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15490,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with lung cancer harboring a germline mutation, ERBB2 (HER2) G660D, demonstrated improved symptoms within 30 days of Gilotrif (afatinib) treatment, as well as a 21% reduction in tumor volume in 12 weeks and a durable response that lasted for more than 15 weeks (PMID: 30449325).",
            "molecularProfile": {
                "id": 24165,
                "profileName": "ERBB2 G660D"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13125,
                    "pubMedId": 30449325,
                    "title": "Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30449325"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6972,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G660D in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24165,
                "profileName": "ERBB2 G660D"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7134,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of lung cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",
            "molecularProfile": {
                "id": 5943,
                "profileName": "NOTCH1 positive"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3325,
                    "pubMedId": null,
                    "title": "Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7333,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).",
            "molecularProfile": {
                "id": 24613,
                "profileName": "ERBB2 T798I"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6146,
                    "pubMedId": 25238247,
                    "title": "Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25238247"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7356,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and SCH772984 combination treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 4476,
                "therapyName": "SCH772984 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7357,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Mapk1 expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25299,
                "profileName": "KRAS G12C MAPK1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7358,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Raf1 expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25300,
                "profileName": "KRAS G12C RAF1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7359,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Braf expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25302,
                "profileName": "BRAF dec exp KRAS G12C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7360,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794).",
            "molecularProfile": {
                "id": 25304,
                "profileName": "FGFR1 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7361,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Frs2 expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25306,
                "profileName": "FRS2 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7362,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25308,
                "profileName": "FGFR2 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7363,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25309,
                "profileName": "FGFR3 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7364,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25310,
                "profileName": "FGFR1 dec exp KRAS wild-type"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7367,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture and induced tumor regression in xenograft models (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4477,
                "therapyName": "Ponatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7369,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS wild-type lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 496,
                "profileName": "KRAS wild-type"
            },
            "therapy": {
                "id": 4477,
                "therapyName": "Ponatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7372,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and AZD4547 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4478,
                "therapyName": "AZD4547 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7373,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and BGJ398 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4479,
                "therapyName": "BGJ398 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7374,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Xalkori (crizotinib) demonstrated additive effect at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4480,
                "therapyName": "Crizotinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7375,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iressa (gefitinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4481,
                "therapyName": "Gefitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7376,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Gilotrif (afatinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4482,
                "therapyName": "Afatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7382,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with an inactivating Crebbp mutation demonstrated sensitivity to treatment with C646 in culture and in a xenograft model, resulting in cell growth inhibition and decreased tumor growth (PMID: 26603525).",
            "molecularProfile": {
                "id": 10327,
                "profileName": "CREBBP inact mut"
            },
            "therapy": {
                "id": 4483,
                "therapyName": "C646",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6332,
                    "pubMedId": 26603525,
                    "title": "Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603525"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7594,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M-mutant-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7596,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7672,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Platinol (cisplatin) and CBP501 resulted in enhanced tumor growth inhibition in cell line xenograft models of lung cancer, compared to either agent alone (PMID: 17237275).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4547,
                "therapyName": "CBP501 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6450,
                    "pubMedId": 17237275,
                    "title": "Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17237275"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7723,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).",
            "molecularProfile": {
                "id": 2242,
                "profileName": "EGFR pos ERBB2 pos"
            },
            "therapy": {
                "id": 1048,
                "therapyName": "S-222611",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1835,
                    "pubMedId": 24837299,
                    "title": "Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24837299"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7731,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7733,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).",
            "molecularProfile": {
                "id": 25935,
                "profileName": "KRAS G12A MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7845,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SZL-P1-41 decreased Skp2 protein expression, inhibited growth of lung cancer cell lines through Tp53-independent mechanism in culture and in cell line xenograft models (PMID: 23911321).",
            "molecularProfile": {
                "id": 26070,
                "profileName": "SKP2 positive"
            },
            "therapy": {
                "id": 1932,
                "therapyName": "SZL-P1-41",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1605,
                    "pubMedId": 23911321,
                    "title": "Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23911321"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7913,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells over expressing PAXIP1 were sensitive to treatment with Adavosertib (MK-1775) in culture, resulting in increased apoptotic activity (PMID: 27196765).",
            "molecularProfile": {
                "id": 26097,
                "profileName": "PAXIP1 over exp"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6524,
                    "pubMedId": 27196765,
                    "title": "PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196765"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7914,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and Platinol (cisplatin) resulted in a synergistic effect when treating lung cancer cells in culture and a patient derived xenograft (PDX) model of lung cancer, both harboring over expression of PAXIP1 and WEE1 (PMID: 27196765).",
            "molecularProfile": {
                "id": 26104,
                "profileName": "PAXIP1 over exp WEE1 over exp"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6524,
                    "pubMedId": 27196765,
                    "title": "PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196765"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7915,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells over expressing PAXIP1 and negative for WEE1 did not respond to treatment with Adavosertib (MK-1775) in culture, demonstrating no effect on apoptotic activity (PMID: 27196765).",
            "molecularProfile": {
                "id": 26103,
                "profileName": "PAXIP1 over exp WEE1 neg"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6524,
                    "pubMedId": 27196765,
                    "title": "PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196765"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and Platinol (cisplatin) resulted in a synergistic effect when treating PAXIP1 and WEE1 positive lung cancer cells in culture (PMID: 27196765).",
            "molecularProfile": {
                "id": 26102,
                "profileName": "PAXIP1 pos WEE1 pos"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6524,
                    "pubMedId": 27196765,
                    "title": "PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196765"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and Platinol (cisplatin) did not result in a synergistic effect when treating lung cancer cells expressing only PAXIP1 in culture (PMID: 27196765).",
            "molecularProfile": {
                "id": 26100,
                "profileName": "PAXIP1 positive"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6524,
                    "pubMedId": 27196765,
                    "title": "PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196765"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8012,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 4620,
                "therapyName": "APS-2-79 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6534,
                    "pubMedId": 27556948,
                    "title": "Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556948"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8015,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APS-2-49 and Binimetinib (MEK162) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 4621,
                "therapyName": "APS-2-79 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6534,
                    "pubMedId": 27556948,
                    "title": "Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556948"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8016,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APS-2-49 and PD-0325901 worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 4623,
                "therapyName": "APS-2-79 + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6534,
                    "pubMedId": 27556948,
                    "title": "Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556948"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8017,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APS-2-49 and Selumetinib (AZD6244) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 4622,
                "therapyName": "APS-2-79 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6534,
                    "pubMedId": 27556948,
                    "title": "Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556948"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8065,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited proliferation of Egfr over expressing lung cancer cells in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8083,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced Erk phosphorylation and inhibited growth of transformed lung epithelial cells expressing ARAF S214C in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 359,
                "profileName": "ARAF S214C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8084,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced Erk phosphorylation and inhibited growth of transformed lung epithelial cells expressing ARAF S214F in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 1129,
                "profileName": "ARAF S214F"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8086,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced Erk phosphorylation and inhibited growth of transformed lung epithelial cells expressing ARAF S214T in culture (PMID: 24569458).",
            "molecularProfile": {
                "id": 1130,
                "profileName": "ARAF S214T"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 251,
                    "pubMedId": 24569458,
                    "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8249,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8255,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53-null lung cancer cells were resistant to KRT-232 (AMG 232) induced growth inhibition in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8256,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8261,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) did not enhance radiation-induced cytotoxicity in TP53-null lung cancer cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8276,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor suppression in lung cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8279,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Apatinib (YN968D1) inhibited tumor growth in lung cancer cell line xenograft models (PMID: 21443688).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 986,
                "therapyName": "Apatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 592,
                    "pubMedId": 21443688,
                    "title": "YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21443688"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8303,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells expressing EGFR and ERBB3 (HER3) demonstrated sensitivity to treatment with MEHD7945A in culture, resulting in decreased cell proliferation (PMID: 26141946).",
            "molecularProfile": {
                "id": 26226,
                "profileName": "EGFR pos ERBB3 pos"
            },
            "therapy": {
                "id": 806,
                "therapyName": "Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6593,
                    "pubMedId": 26141946,
                    "title": "Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26141946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8561,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rigosertib (ON 01910.Na) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of lung cancer harboring KRAS G12S (PMID: 27104980).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6686,
                    "pubMedId": 27104980,
                    "title": "A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27104980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8619,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovotine (seliciclib) induced apoptosis and inhibited growth of CCNE1 (cyclin E)-dependent murine lung cancer cell lines in culture, and demonstrated anti-tumor activity in mouse models (PMID: 20028770).",
            "molecularProfile": {
                "id": 1805,
                "profileName": "CCNE1 over exp"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6702,
                    "pubMedId": 20028770,
                    "title": "Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20028770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9028,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9029,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).",
            "molecularProfile": {
                "id": 25935,
                "profileName": "KRAS G12A MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9074,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to PU-H71 was correlated to presence of the epichaperome, a network of chaperome complexes, in lung cancer cell lines in culture (PMID: 27706135).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1162,
                "therapyName": "PU-H71",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6895,
                    "pubMedId": 27706135,
                    "title": "The epichaperome is an integrated chaperome network that facilitates tumour survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27706135"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9141,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dinaciclib (SCH 727965) inhibited proliferation of lung cancer cell lines through Cdk1 and Cdk2 inhibition in culture (PMID: 27550941).",
            "molecularProfile": {
                "id": 26750,
                "profileName": "CDK1 pos CDK2 pos"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6931,
                    "pubMedId": 27550941,
                    "title": "Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550941"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Dinaciclib (SCH 727965) and Taxol (paclitaxel) demonstrated enhanced growth inhibition in lung cancer cell lines in culture (PMID: 27550941).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4912,
                "therapyName": "Dinaciclib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6931,
                    "pubMedId": 27550941,
                    "title": "Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550941"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9147,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RN927C demonstrated cytotoxicity in Tacstd2 (Trop-2)-expressing lung cancer cell lines in culture, and inhibited tumor growth in a lung cancer patient-derived xenograft (PDX) model (PMID: 27582525).",
            "molecularProfile": {
                "id": 26744,
                "profileName": "TACSTD2 positive"
            },
            "therapy": {
                "id": 4913,
                "therapyName": "RN927C",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6932,
                    "pubMedId": 27582525,
                    "title": "RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582525"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9445,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IPI-549 inhibited tumor growth in cell line xenograft models of lung cancer through reducing the immune-suppressive tumor-associated myeloid cells (PMID: 27828943).",
            "molecularProfile": {
                "id": 26851,
                "profileName": "PIK3CG positive"
            },
            "therapy": {
                "id": 3363,
                "therapyName": "IPI-549",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7194,
                    "pubMedId": 27828943,
                    "title": "Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27828943"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9566,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring EGFR L858R in culture, and inhibited tumor growth in xenograft models (PMID: 27928026).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9567,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with AZD3759 inhibited EGFR activity and demonstrated antitumor activity in two patients with non-small cell lung cancer harboring EGFR L858R, resulting in decreased CSF tumor cell number in the patient with leptomeningeal metastasis, and decreased brain tumor growth in the patient with brain metastasis (PMID: 27928026).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9568,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring an EGFR exon 19 deletion in culture and induced tumor regression in subcutaneous xenograft models, and inhibited tumor growth in brain and leptomeningeal xenograft models (PMID: 27928026).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9569,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M did not demonstrate sensitivity to AZD3759 in culture (PMID: 27928026).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9743,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ABT-737 and perifosine worked synergistically to induce apoptosis and inhibit growth of lung cancer cell lines and primary lung cancer cells in culture, and to inhibit tumor growth in a lung cancer cell line xenograft model (PMID: 27073162).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5187,
                "therapyName": "ABT-737 + Perifosine",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7520,
                    "pubMedId": 27073162,
                    "title": "Perifosine and ABT-737 synergistically inhibit lung cancer cells in\u00a0vitro and in\u00a0vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27073162"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9761,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-06647020 decreased viability of PTK7-expressing lung cancer cell lines in culture (PMID: 28077676).",
            "molecularProfile": {
                "id": 24719,
                "profileName": "PTK7 positive"
            },
            "therapy": {
                "id": 4421,
                "therapyName": "PF-06647020",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7557,
                    "pubMedId": 28077676,
                    "title": "A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28077676"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9791,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Aurora Kinase Inhibitor II (AI II) decreased viability of transformed lung cells expressing KRAS G12V in culture (PMID: 26842935).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 5230,
                "therapyName": "Aurora Kinase Inhibitor II",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7603,
                    "pubMedId": 26842935,
                    "title": "Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26842935"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9828,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) inhibited proliferation of several lung cancer cell lines in culture, including squamous, adenocarcinoma, large cell, and small celll lung cancer cell lines (PMID: 22576795).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7651,
                    "pubMedId": 22576795,
                    "title": "Antiproliferative action of metformin in human lung cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22576795"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10021,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MYC T58A in a lung cancer cell line harboring FGFR1 amplification reduced sensitivity to AZD4547 in culture and in xenograft models (PMID: 27401245).",
            "molecularProfile": {
                "id": 27225,
                "profileName": "FGFR1 amp MYC T58A"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10023,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MYC T58A in a lung cancer cell line harboring FGFR1 amplification reduced sensitivity to BGJ398 in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 27225,
                "profileName": "FGFR1 amp MYC T58A"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10255,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant lung cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10260,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of CDKN2A-deleted lung cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 6542,
                "profileName": "CDKN2A del"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10335,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CT16 treatment decreased NOTCH and EGFR signaling and inhibited tumor growth in lung cancer patient-derived xenograft (PDX) models sensitive to EGFR blockade (PMID: 28275151).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5472,
                "therapyName": "CT16",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8315,
                    "pubMedId": 28275151,
                    "title": "Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28275151"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10343,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, X-376 inhibited Alk signaling, resulted in growth inhibition in lung cancer cells harboring EML4-ALK fusion in culture and in cell line xenograft models (PMID: 21613408).",
            "molecularProfile": {
                "id": 4138,
                "profileName": "EML4 - ALK"
            },
            "therapy": {
                "id": 2520,
                "therapyName": "X-376",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2442,
                    "pubMedId": 21613408,
                    "title": "Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21613408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10677,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of YES1 in a lung cancer cell line with an EGFR exon 19 deletion and T790M promoted acquired resistance to Tagrisso (osimertinib) in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27725,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 over exp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10678,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to Tagrisso (osimertinib) therapy inhibited growth of a Tagrisso (osimertinib)-resistant lung cancer cell line harboring an EGFR exon 19 deletion and EGFR T790M with YES1 amplification and over expression in culture, and reduced tumor growth in xenograft models (PMID: 28416483).",
            "molecularProfile": {
                "id": 27724,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TC-A2317 inhibited growth, induced apoptosis in lung cancer cell lines in culture (PMID: 27713168).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5579,
                "therapyName": "TC-A2317",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8740,
                    "pubMedId": 27713168,
                    "title": "The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713168"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1019,
                "therapyName": "Golvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 41,
                    "pubMedId": 19832844,
                    "title": "E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19832844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10879,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 7RH treatment resulted in tumor regression in KRAS G12V-driven animal models of lung cancer with elevated Ddr1 expression (PMID: 26855149).",
            "molecularProfile": {
                "id": 27815,
                "profileName": "DDR1 over exp KRAS G12V"
            },
            "therapy": {
                "id": 5669,
                "therapyName": "7RH",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10880,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 7RH treatment had no effect on tumor growth in KRAS G12V-driven animal models of lung cancer with DDR1 knockout background (PMID: 26855149).",
            "molecularProfile": {
                "id": 27817,
                "profileName": "DDR1 del KRAS G12V"
            },
            "therapy": {
                "id": 5669,
                "therapyName": "7RH",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10881,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 7RH and LY411575 combination treatment resulted in additive effect on apoptosis in KRAS G12V-driven animal models of lung cancer (PMID: 26855149).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 5670,
                "therapyName": "7RH + LY411575",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10882,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 7RH treatment had no effect on tumor cell apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",
            "molecularProfile": {
                "id": 27818,
                "profileName": "KRAS G12V TP53 del"
            },
            "therapy": {
                "id": 5669,
                "therapyName": "7RH",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10883,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 7RH and LY411575 combination treatment induced apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",
            "molecularProfile": {
                "id": 27818,
                "profileName": "KRAS G12V TP53 del"
            },
            "therapy": {
                "id": 5670,
                "therapyName": "7RH + LY411575",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11013,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-014 inhibited growth of HAVCR1-positive lung cancer cells in culture, resulted in anti-tumor activity and improved survival in cell line xenograft models (PMID: 27671527).",
            "molecularProfile": {
                "id": 27883,
                "profileName": "HAVCR1 positive"
            },
            "therapy": {
                "id": 5774,
                "therapyName": "CDX-014",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8982,
                    "pubMedId": 27671527,
                    "title": "Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671527"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11124,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and AZ628 resulted in greater inhibition of Mek and apoptosis in a non-BRAF V600 mutant lung cancer cell line in culture compared to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (J Clin Oncol 35, 2017 (suppl; abstr e23154)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4795,
                "therapyName": "AZ628 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9096,
                    "pubMedId": null,
                    "title": "Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer",
                    "url": "http://abstracts.asco.org/199/AbstView_199_191661.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11179,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited FGFR downstream signaling and proliferation of several lung cancer cell lines with FGFR1 amplification in culture, and inhibited tumor growth in an FGFR1-amplified lung cancer cell line xenograft model (PMID: 28341788).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11184,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).",
            "molecularProfile": {
                "id": 27922,
                "profileName": "EGFR amp FGFR1 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11185,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).",
            "molecularProfile": {
                "id": 27923,
                "profileName": "EGFR amp FGFR1 amp KRAS G13C"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11186,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring FGFR1 amplification and KRAS G12V demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).",
            "molecularProfile": {
                "id": 27924,
                "profileName": "FGFR1 amp KRAS G12V"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11187,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and KRAS demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).",
            "molecularProfile": {
                "id": 27925,
                "profileName": "FGFR1 amp KRAS amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11302,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquisition of YES1 amplification in a lung cancer cell line harboring an EGFR exon 19 deletion and EGFR T790M was associated with resistance to Tagrisso (osimertinib) in culture and in xenograft models (PMID: 28416483).",
            "molecularProfile": {
                "id": 27946,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11303,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) and Sprycel (dasatinib) in combination resulted in increased PARP cleavage and inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M compared to Tagrisso (osimertinib) alone, and inhibited tumor growth in xenograft models, with 3 out of 7 models demonstrating no tumor rebound after cessation of therapy (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GSK2334470 and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5936,
                "therapyName": "GSK2334470 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of TAK-632 and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5937,
                "therapyName": "Osimertinib + TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Saracatinib (AZD0530) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5938,
                "therapyName": "Osimertinib + PF-573228 + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Bosulif (bosutinib) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5939,
                "therapyName": "Bosutinib + Osimertinib + PF-573228",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11311,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11312,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 4600,
                "therapyName": "Dasatinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11313,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11314,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11317,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11318,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11332,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4785 inhibited Kras expression and downstream signaling, resulted in tumor growth inhibition in patient-derived xenograft models of lung cancer harboring KRAS G12C (PMID: 28615361).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11389,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, resulted in growth inhibition and apoptosis in KRAS mutant lung cancer cell lines in culture, and in both cell line and patient-derived xenograft models (PMID: 28504649).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11390,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing Ppp2r1a (PMID: 28504649).",
            "molecularProfile": {
                "id": 27982,
                "profileName": "KRAS mut PPP2R1A over exp"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11391,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MK2206 combination treatment inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing Ppp2r1a (PMID: 28504649).",
            "molecularProfile": {
                "id": 27982,
                "profileName": "KRAS mut PPP2R1A over exp"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11392,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A E197K (PMID: 28504649).",
            "molecularProfile": {
                "id": 27985,
                "profileName": "KRAS mut PPP2R1A E197K"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11393,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MK2206 combination treatment inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A E197K (PMID: 28504649).",
            "molecularProfile": {
                "id": 27985,
                "profileName": "KRAS mut PPP2R1A E197K"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11394,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MK2206 combination treatment inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A K194R (PMID: 28504649).",
            "molecularProfile": {
                "id": 27984,
                "profileName": "KRAS mut PPP2R1A K194R"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11395,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MK2206 combination treatment inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A L198V (PMID: 28504649).",
            "molecularProfile": {
                "id": 27983,
                "profileName": "KRAS mut PPP2R1A L198V"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11396,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 failed to induce apoptosis, inhibit Mapk signaling and tumor growth in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A K194R (PMID: 28504649).",
            "molecularProfile": {
                "id": 27984,
                "profileName": "KRAS mut PPP2R1A K194R"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11397,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 failed to induce apoptosis, inhibit Mapk signaling and tumor growth in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A L198V (PMID: 28504649).",
            "molecularProfile": {
                "id": 27983,
                "profileName": "KRAS mut PPP2R1A L198V"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11407,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 9F7-F11 inhibited tumor growth and improved survival in a lung cancer cell line xenograft model expressing low levels of NRG1 (PMID: 28507002).",
            "molecularProfile": {
                "id": 23513,
                "profileName": "NRG1 positive"
            },
            "therapy": {
                "id": 5976,
                "therapyName": "9F7-F11",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9293,
                    "pubMedId": 28507002,
                    "title": "Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28507002"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11476,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (56% vs 22%) in cell line xenograft models of FGFR1 amplified lung cancer compared to FGFR1 non-amplified models (PMID: 23536011).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 2899,
                "therapyName": "GSK3052230",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9409,
                    "pubMedId": 23536011,
                    "title": "Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23536011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11596,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 selectively inhibited growth of lung cancer cell lines with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11767,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET exon 14 deletion demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET del exon14 MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11904,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Mekinist (trametinib) in a lung cancer cell line harboring BRAF V600E in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28339,
                "profileName": "BRAF V600E KEAP1 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Zelboraf (vemurafenib) in a lung cancer cell line harboring BRAF V600E in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28339,
                "profileName": "BRAF V600E KEAP1 loss"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Mekinist (trametinib) in a lung cancer cell line harboring NRAS Q61K in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28337,
                "profileName": "KEAP1 loss NRAS Q61K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11908,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Mekinist (trametinib) in a lung cancer cell line harboring KRAS G12C in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28338,
                "profileName": "KEAP1 loss KRAS G12C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11909,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Tarceva (erlotinib) in a lung cancer cell line harboring EGFR E746_A750del in culture and in xenograft models (PMID: 28145866).",
            "molecularProfile": {
                "id": 28342,
                "profileName": "EGFR E746_A750del KEAP1 loss"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11910,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Xalkori (crizotinib) in a lung cancer cell line and patient-derived lung cancer cells harboring EML4-ALK in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28935,
                "profileName": "EML4 - ALK KEAP1 dec exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11911,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Zykadia (ceritinib) in patient-derived lung cancer cells harboring EML4-ALK in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28935,
                "profileName": "EML4 - ALK KEAP1 dec exp"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11912,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Gilotrif (afatinib) in a lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of wild-type NFE2L2 (NRF2) resulted in decreased sensitivity to Tarceva (erlotinib) in a lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28353,
                "profileName": "EGFR E746_A750del NFE2L2 over exp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of wild-type NFE2L2 (NRF2) resulted in decreased sensitivity to Zelboraf (vemurafenib) in a lung cancer cell line harboring BRAF V600E in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28348,
                "profileName": "BRAF V600E NFE2L2 over exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11918,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of NFE2L2 (NRF2) G31R resulted in decreased sensitivity to Zelboraf (vemurafenib) in a lung cancer cell line harboring BRAF V600E in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28345,
                "profileName": "BRAF V600E NFE2L2 G31R NFE2L2 over exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11919,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of NFE2L2 (NRF2) G31R resulted in decreased sensitivity to Mekinist (trametinib) in a lung cancer cell line harboring BRAF V600E in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28345,
                "profileName": "BRAF V600E NFE2L2 G31R NFE2L2 over exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of NFE2L2 (NRF2) G31R resulted in decreased sensitivity to Mekinist (trametinib) in a lung cancer cell line harboring KRAS G12C in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28346,
                "profileName": "KRAS G12C NFE2L2 G31R NFE2L2 over exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of NFE2L2 (NRF2) D29H resulted in decreased sensitivity to Tarceva (erlotinib) in a lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28352,
                "profileName": "EGFR E746_A750del NFE2L2 D29H NFE2L2 over exp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12258,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28613,
                "profileName": "FGFR1 amp MET dec exp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12259,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to AZD4547 in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28614,
                "profileName": "FGFR1 amp MET pos"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12260,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rogaratinib (BAY 1163877) inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28613,
                "profileName": "FGFR1 amp MET dec exp"
            },
            "therapy": {
                "id": 2030,
                "therapyName": "Rogaratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12262,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to Rogaratinib (BAY 1163877) in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28614,
                "profileName": "FGFR1 amp MET pos"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12264,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET amplification was identified as the mechanism mediating acquired AZD4547 resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28587,
                "profileName": "FGFR1 amp MET amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12265,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET overexpression and activation was identified as the mechanism mediating acquired Rogaratinib (BAY 1163877) resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28586,
                "profileName": "FGFR1 amp MET over exp"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to AZD4547 through MET amplification in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28587,
                "profileName": "FGFR1 amp MET amp"
            },
            "therapy": {
                "id": 6398,
                "therapyName": "AZD4547 + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12267,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rogaratinib (BAY 1163877) and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to Rogaratinib (BAY 1163877) through MET overexpression and activation in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28586,
                "profileName": "FGFR1 amp MET over exp"
            },
            "therapy": {
                "id": 6399,
                "therapyName": "Crizotinib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth of MET-amplified lung cancer cells in culture (PMID: 28765324).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12326,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in lung cancer cells harboring a deletion of MET exon 14 and loss of the wild-type MET allele in culture (PMID: 28765324).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12353,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in both cell line xenograft and patient-derived xenograft (PDX) models of lung cancer with high Met expression (PMID: 28679766).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12356,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12371,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 803,
                "therapyName": "Emibetuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12372,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment resulted in tumor growth inhibition in patient-derived xenograft (PDX) models of MET-amplified lung cancer harboring EGFR activating mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 28681,
                "profileName": "EGFR act mut MET amp"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12416,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Selpercatinib (LOXO-292) treatment resulted in a partial response and a 44% reduction of tumor size in a lung cancer patient harboring CCDC6-RET with acquired resistance to RXDX-105 (J Thorac Oncol, Nov 2017, 12 (11): Suppl 2, Page S1778, abstract OA 12.07).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10370,
                    "pubMedId": null,
                    "title": "LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases",
                    "url": "http://www.jto.org/article/S1556-0864(17)31134-6/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12695,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients with lung cancer each harboring BRAF V600E (PMID: 29247021).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12696,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in a lung cancer patient harboring BRAF L597Q (PMID: 29247021).",
            "molecularProfile": {
                "id": 993,
                "profileName": "BRAF L597Q"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12883,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-8800 preferentially inhibited growth of lung cancer cells harboring U2AF1 S34F compared to U2AF1 wild-type cells in culture and in cell line xenograft models (Cancer Res 2017;77(13 Suppl):Abstract nr 1185).",
            "molecularProfile": {
                "id": 23592,
                "profileName": "U2AF1 S34F"
            },
            "therapy": {
                "id": 6685,
                "therapyName": "H3B-8800",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10830,
                    "pubMedId": null,
                    "title": "H3B-8800, a novel orally available SF3b modulator, shows preclinical efficacy across spliceosome mutant cancers",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/1185.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13087,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GTx-186 inhibited Ros1 phosphorylation and growth of lung cancer cells harboring SLC34A2-ROS1 fusion in culture (PMID: 24386191).",
            "molecularProfile": {
                "id": 10084,
                "profileName": "SLC34A2 - ROS1"
            },
            "therapy": {
                "id": 2675,
                "therapyName": "GTx-186",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2718,
                    "pubMedId": 24386191,
                    "title": "Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24386191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13552,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in lung cancer cell line xenograft models harboring KRAS G12D (Cancer Res 2010;70(8 Suppl):Abstract nr 4484).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3850,
                "therapyName": "AR-mTOR-26",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5033,
                    "pubMedId": null,
                    "title": "Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/4484.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13572,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Triolimus led to cytotoxicity and inhibited Ras/Raf/MAPK and PI3K/Akt/mTOR pathway signaling in lung cancer cells in culture, and induced apoptosis, which resulted in tumor growth inhibition, in cell line xenograft models (PMID: 22896668).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3855,
                "therapyName": "Triolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5037,
                    "pubMedId": 22896668,
                    "title": "Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22896668"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13746,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, two lung cancer patients harboring CD74-NRG1 did not respond to Gilotrif (afatinib) treatment (PMID: 29610121; NCT01966445).",
            "molecularProfile": {
                "id": 15038,
                "profileName": "CD74 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11263,
                    "pubMedId": 29610121,
                    "title": "Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29610121"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13747,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung cancer patient harboring SDC4-NRG1 did not respond to treatment with Gilotrif (afatinib) (PMID: 29610121; NCT01966445).",
            "molecularProfile": {
                "id": 28756,
                "profileName": "SDC4 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11263,
                    "pubMedId": 29610121,
                    "title": "Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29610121"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13821,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BA3021 (CAB-ROR2-ADC) inhibited growth of Ror2-positive lung cancer cells in culture and in cell line xenograft models (Proceedings of the AACR, Apr 2018, Vol 59, Abstract 833).",
            "molecularProfile": {
                "id": 29507,
                "profileName": "ROR2 positive"
            },
            "therapy": {
                "id": 6906,
                "therapyName": "BA3021",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11293,
                    "pubMedId": null,
                    "title": "Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/833"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13831,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1, in culture and in xenograft models (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3461,
                "therapyName": "NTRC 0066-0",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3451,
                "therapyName": "Mps-BAY2b",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3445,
                "therapyName": "BAY1161909",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3446,
                "therapyName": "BAY1217389",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13855,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3424,
                "therapyName": "Mps1-IN-1",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13863,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3458,
                "therapyName": "MPI-0479605",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13870,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Camrelizumab (SHR-1210) demonstrated safety and preliminary anti-tumor activity, resulted in partial response in 33.3% (1/3) of patients with lung cancer (J Clin Onc. 2017 35:15_suppl, e15572-e15572; NCT02742935).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6137,
                "therapyName": "Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9759,
                    "pubMedId": null,
                    "title": "Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15572"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13991,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR A767_V769dup in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 27532,
                "profileName": "EGFR A767_V769dup"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13992,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR N771_H773dup in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13993,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR S768_D770dup in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 13009,
                "profileName": "EGFR S768_D770dup"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13994,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR exon 20 insertions in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13995,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) decreased Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR A767_V769dup in culture, bud did not affect tumor growth in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 27532,
                "profileName": "EGFR A767_V769dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13996,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) decreased Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR N771_H773dup in culture, bud did not affect tumor growth in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14041,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth and induced apoptotic markers in a lung cancer patient-derived xenograft (PDX) model-derived cell line harboring EGFR A767_V769dup (reported as V769_D770insASV) in culture, and inhibited tumor growth and induced tumor regression in PDX models (PMID: 29748209).",
            "molecularProfile": {
                "id": 27532,
                "profileName": "EGFR A767_V769dup"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14042,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth and induced apoptotic markers in a lung cancer cell line expressing EGFR S768_D770dup (reported as D770_N771insSVD) in culture, inhibited tumor growth and induced tumor regression in subcutaneous xenograft models, and prolonged survival in intrapulmonary xenograft models (PMID: 29748209).",
            "molecularProfile": {
                "id": 13009,
                "profileName": "EGFR S768_D770dup"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14043,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited tumor growth in lung cancer patient-derived xenograft (PDX) models harboring EGFR N771_H773dup (reported as H773_V774insNPH) (PMID: 29748209).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth of lung cancer cell lines harboring EGFR E746_A750del in culture (PMID: 29748209).",
            "molecularProfile": {
                "id": 624,
                "profileName": "EGFR E746_A750del"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth of a lung cancer cell line harboring EGFR L858R and EGFR T790M in culture (PMID: 29748209).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14050,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 inhibited Erk signaling and proliferation of lung cancer cells harboring NRAS Q61K in culture, and resulted in tumor regression in cell line xenograft models (PMID: 29343524).",
            "molecularProfile": {
                "id": 646,
                "profileName": "NRAS Q61K"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14189,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1390 inhibited Atm activity, sensitized lung cancer cells to radiotherapy in culture, and demonstrated efficacy in cell line xenograft models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).",
            "molecularProfile": {
                "id": 20966,
                "profileName": "ATM positive"
            },
            "therapy": {
                "id": 7032,
                "therapyName": "AZD1390",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11499,
                    "pubMedId": null,
                    "title": "AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14392,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung cancer patient harboring EGFR L858R developed resistance to Tarceva (erlotinib) treatment and was subsequently found to have acquired a secondary resistance mutation, MTOR E2419K (PMID: 29530932).",
            "molecularProfile": {
                "id": 30015,
                "profileName": "EGFR L858R MTOR E2419K"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11632,
                    "pubMedId": 29530932,
                    "title": "Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29530932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14737,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring EGFR P772_H773insGNP (referred to as D770_N771insNPG), with no signs of progression at 12 weeks (PMID: 29686424).",
            "molecularProfile": {
                "id": 23636,
                "profileName": "EGFR P772_H773insGNP"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14744,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA), with no signs of progression at 12 weeks (PMID: 29686424).",
            "molecularProfile": {
                "id": 3148,
                "profileName": "ERBB2 Y772_A775dup"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15062,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring FGFR1 amplification demonstrated resistance to increasing concentrations of PD173074 in culture and was subsequently, found to have acquired AKT1 S266L (PMID: 30140389).",
            "molecularProfile": {
                "id": 30722,
                "profileName": "AKT1 S266L FGFR1 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12589,
                    "pubMedId": 30140389,
                    "title": "Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30140389"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15063,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring FGFR1 amplification were sensitive to PD173074 treatment in culture, demonstrating inhibition of cell growth (PMID: 30140389).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12589,
                    "pubMedId": 30140389,
                    "title": "Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30140389"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15064,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring FGFR1 amplification and AKT1 S266L demonstrated sensitivity to Uprosertib (GSK2141795) in culture, showing decreased phosphorylation of Akt1 targets and reduced cell growth (PMID: 30140389).",
            "molecularProfile": {
                "id": 30722,
                "profileName": "AKT1 S266L FGFR1 amp"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12589,
                    "pubMedId": 30140389,
                    "title": "Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30140389"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15179,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MGC018 demonstrated anti-tumor activity in cell line xenograft models of CD276 (B7-H3)-positive lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 820).",
            "molecularProfile": {
                "id": 27908,
                "profileName": "CD276 positive"
            },
            "therapy": {
                "id": 7459,
                "therapyName": "MGC018",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12775,
                    "pubMedId": null,
                    "title": "Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15233,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines and xenografts, overexpressing Fen1, were resistant to cisplatin treatment, as demonstrated by decreased apoptosis, reduced cells in G1 phase, and decreased tumor growth (PMID: 28371273).",
            "molecularProfile": {
                "id": 30880,
                "profileName": "FEN1 over exp"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12952,
                    "pubMedId": 28371273,
                    "title": "FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28371273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15267,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, NTRK1 G595R and NTRK1 G667S were identified at disease progression in a patient with lung cancer harboring TPR-NTRK1 treated with Vitrakvi (larotrectinib) (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 30926,
                "profileName": "TPR - NTRK1 NTRK1 G595R NTRK1 G667S"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15366,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of wild-type MAST1 conferred resistance to Platinol (cisplatin) in a lung cancer cell line in culture (PMID: 30033091).",
            "molecularProfile": {
                "id": 30988,
                "profileName": "MAST1 over exp"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13112,
                    "pubMedId": 30033091,
                    "title": "MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30033091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15369,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lestaurtinib (CEP-701) resensitized lung cancer cells overexpressing wild-type MAST1 to Platinol (cisplatin) in culture (PMID: 30033091).",
            "molecularProfile": {
                "id": 30988,
                "profileName": "MAST1 over exp"
            },
            "therapy": {
                "id": 7590,
                "therapyName": "Cisplatin + Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13112,
                    "pubMedId": 30033091,
                    "title": "MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30033091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15984,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit Erk phosphorylation or proliferation of lung cancer cells harboring BRAF G469A in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15985,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of lung cancer cells harboring BRAF G466V in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15988,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 decreased RAS-GTP level, inhibited Erk phosphorylation and proliferation of lung cancer cells harboring NF1 N184fs in culture, resulted in tumor regression in cell line xenograft models (PMID: 30104724).",
            "molecularProfile": {
                "id": 31355,
                "profileName": "NF1 N184fs"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15990,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of PTPN11 E76K in lung cancer cells harboring NF1 N184fs abolished their sensitivity to RMC-4550-induced inhibition of Erk phosphorylation and proliferation in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 31356,
                "profileName": "NF1 N184fs PTPN11 E76K"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15994,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited proliferation of lung cancer cells harboring NF1 C1032fs in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 31358,
                "profileName": "NF1 C1032fs"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15995,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited proliferation of lung cancer cell lines harboring KRAS G12A in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 2381,
                "profileName": "KRAS G12A"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15996,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 decreased RAS-GTP level, inhibited Erk phosphorylation and proliferation of lung cancer cell lines harboring KRAS G12C in culture, resulted in dose-dependent tumor growth inhibition in cell line xenograft models (PMID: 30104724).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16004,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of lung cancer cells harboring KRAS Q61K in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1864,
                "profileName": "KRAS Q61K"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16005,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of lung cancer cell lines harboring KRAS Q61H in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1862,
                "profileName": "KRAS Q61H"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16008,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of colorectal cancer cells harboring KRAS G13D in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 811,
                "profileName": "KRAS G13D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16010,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited growth in 2 of 3 lung cancer cell lines harboring KRAS G12V in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1127,
                "profileName": "KRAS G12V"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16014,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of lung cancer cells harboring KRAS G12S in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16019,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of lung cancer cells harboring KRAS G12D in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16548,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) demonstrated safety and preliminary efficacy, resulted in stable disease as best overall response in 2 patients with lung cancer (PMID: 30724423).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14616,
                    "pubMedId": 30724423,
                    "title": "Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30724423"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16624,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OTS193320 inhibited growth of a SUV39H2-expressing lung cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 30159125).",
            "molecularProfile": {
                "id": 31712,
                "profileName": "SUV39H2 positive"
            },
            "therapy": {
                "id": 8109,
                "therapyName": "OTS193320",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14641,
                    "pubMedId": 30159125,
                    "title": "Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30159125"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16626,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OTS193320 and Adriamycin (doxorubicin) had an additive effect on tumor growth inhibition in SUV39H2-positive lung cancer cell line xenograft models (PMID: 30159125).",
            "molecularProfile": {
                "id": 31712,
                "profileName": "SUV39H2 positive"
            },
            "therapy": {
                "id": 8110,
                "therapyName": "Doxorubicin + OTS193320",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14641,
                    "pubMedId": 30159125,
                    "title": "Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30159125"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16772,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS0728 inhibited Erbb2 downstream signaling and proliferation of ERBB2 (HER2) amplified lung cancer cells in culture (PMID: 30787176).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 8170,
                "therapyName": "TAS0728",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14833,
                    "pubMedId": 30787176,
                    "title": "TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30787176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16839,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of lung cancer harboring MET amplification and MET exon 14 deletion (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET del exon14 MET amp"
            },
            "therapy": {
                "id": 8205,
                "therapyName": "TPX-0022",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14951,
                    "pubMedId": null,
                    "title": "TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16874,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of lung cancer harboring CD74-ROS1 (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1319).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14995,
                    "pubMedId": null,
                    "title": "Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17241,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VB-111 treatment resulted in increased tumor lymphocyte infiltration and reduced tumor burden in animal models of lung cancer (AACR Annual Meeting 2019, Abstract 4979).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2276,
                "therapyName": "VB-111",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15256,
                    "pubMedId": null,
                    "title": "Ofranergene Obadenovec (VB-111), an anti-cancer gene therapy, induces immunologic responses in solid tumors transforming cold tumors to hot tumors",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/3761"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17252,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Sapanisertib (MLN0128) treatment of a squamous cell lung cancer patient, harboring NFE2L2 D29H, resulted in a duration of response of 8 months and was ongoing (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 9098-9098).",
            "molecularProfile": {
                "id": 11072,
                "profileName": "NFE2L2 D29H"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15272,
                    "pubMedId": null,
                    "title": "Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17253,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Sapanisertib (MLN0128) treatment of a squamous cell lung cancer patient, harboring NFE2L2 F37V, resulted in a duration of response of 5.5 months and was ongoing (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 9098-9098).",
            "molecularProfile": {
                "id": 32398,
                "profileName": "NFE2L2 F37V"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15272,
                    "pubMedId": null,
                    "title": "Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17254,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Sapanisertib (MLN0128) treatment of a squamous cell lung cancer patient, harboring NFE2L2 W24C, resulted in a duration of response of 1 month and was ongoing (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 9098-9098).",
            "molecularProfile": {
                "id": 11079,
                "profileName": "NFE2L2 W24C"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15272,
                    "pubMedId": null,
                    "title": "Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited Erk signaling, resulted in reduced proliferation and invasion of transformed lung epithelial cells expressing KIAA1217-RET in culture (PMID: 27150058).",
            "molecularProfile": {
                "id": 32440,
                "profileName": "KIAA1217 - RET"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15222,
                    "pubMedId": 27150058,
                    "title": "Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27150058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17267,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed lung epithelial cells expressing KIAA1217-RET in culture (PMID: 27150058).",
            "molecularProfile": {
                "id": 32440,
                "profileName": "KIAA1217 - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15222,
                    "pubMedId": 27150058,
                    "title": "Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27150058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17268,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) did not inhibit proliferation of transformed lung epithelial cells expressing KIAA1217-RET in culture (PMID: 27150058).",
            "molecularProfile": {
                "id": 32440,
                "profileName": "KIAA1217 - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15222,
                    "pubMedId": 27150058,
                    "title": "Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27150058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17379,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABX9xx inhibited Egfr and Met downstream signaling in several lung cancer cell lines harboring both EGFR and MET mutations in culture (AACR Annual Meeting 2019, Abstract 4830).",
            "molecularProfile": {
                "id": 32522,
                "profileName": "EGFR mut MET mut"
            },
            "therapy": {
                "id": 8471,
                "therapyName": "ABX9xx",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15402,
                    "pubMedId": null,
                    "title": "ABX9xx: A bispecific centyrin that synergizes to attenuate intracellular signaling in Met/EGFR positive tumors",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/3146"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17577,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A was resistant to Tafinlar (dabrafenib), as demonstrated by increased cell viability and elevated Erk phosphorylation in culture (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17578,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A was resistant to Zelboraf (vemurafenib), as demonstrated by increased cell viability and elevated Erk phosphorylation in culture (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17579,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A was resistant to Nexavar (sorafenib), as demonstrated by increased cell viability and elevated Erk phosphorylation in culture (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17580,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A demonstrated sensitivity to LY3009120 resulting in decreased phosphorylation of Erk in culture and decreased cell viability (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17581,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A demonstrated sensitivity to AZ628 resulting in decreased phosphorylation of Erk in culture and decreased cell viability (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed human lung epithelial cell line expressing RAF1 P261A demonstrated enhanced sensitivity to the combination of Mekinist (trametinib) and LY3009120, resulting in decreased phosphorylation of Erk in culture and decreased cell viability (PMID: 31285551).",
            "molecularProfile": {
                "id": 8770,
                "profileName": "RAF1 P261A"
            },
            "therapy": {
                "id": 8557,
                "therapyName": "LY3009120 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15677,
                    "pubMedId": 31285551,
                    "title": "CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18596,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of lung cancer cells harboring PDGFRA amplification in culture, and resulted in tumor regression in cell line xenograft models (PMID: 31085175).",
            "molecularProfile": {
                "id": 1417,
                "profileName": "PDGFRA amp"
            },
            "therapy": {
                "id": 4316,
                "therapyName": "Ripretinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16041,
                    "pubMedId": 31085175,
                    "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085175"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18666,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JBJ-04-125-02 induced tumor regression in a transgenic mouse model of lung cancer harboring EGFR L858R, T790M and C797S (PMID: 31092401).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR T790M EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 8684,
                "therapyName": "JBJ-04-125-02",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16071,
                    "pubMedId": 31092401,
                    "title": "Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18669,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment resulted in tumor regression in urethane-induced lung cancer harboring KRAS Q61R in mouse models (PMID: 31534020).",
            "molecularProfile": {
                "id": 1865,
                "profileName": "KRAS Q61R"
            },
            "therapy": {
                "id": 8786,
                "therapyName": "Everolimus + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19001,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 inhibited Erk1/2 phosphorylation and viability of lung cancer cell lines harboring KRAS G12C in culture, resulted in tumor regression in cell line xenograft and patient-derived xenograft models (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19005,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of lung cancer cells harboring KRAS G12S in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19006,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of lung cancer cells harboring KRAS G13C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1438,
                "profileName": "KRAS G13C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19007,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of KRAS wild-type lung cancer cells harboring EGFR E746_A750del in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 33810,
                "profileName": "EGFR E746_A750del KRAS wild-type"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19008,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of KRAS wild-type lung cancer cells harboring EML4-ALK in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 33811,
                "profileName": "EML4 - ALK KRAS wild-type"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19011,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Gilotrif (afatinib) synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8873,
                "therapyName": "Afatinib + AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19012,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Tarceva (erlotinib) synergistically inhibited growth of lung cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8874,
                "therapyName": "AMG 510 + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19013,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and RMC-4550 synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8875,
                "therapyName": "AMG 510 + RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19014,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Mekinist (trametinib) synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8876,
                "therapyName": "AMG 510 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19015,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and AMG 511 synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8879,
                "therapyName": "AMG 510 + AMG 511",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19016,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Capivasertib (AZD5363) synergistically inhibited growth of lung cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8877,
                "therapyName": "AMG 510 + Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19023,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and PD-0325901 synergistically inhibited tumor growth in cell line xenograft models of lung cancer harboring KRAS G12C (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8880,
                "therapyName": "AMG 510 + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19024,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of AMG 510 and Paraplatin (carboplatin) demonstrated enhanced tumor growth inhibition in cell line xenograft models of lung cancer harboring KRAS G12C (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8881,
                "therapyName": "AMG 510 + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19026,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of AMG 510 and anti-PD-1 antibody resulted in sustained complete response in mouse syngeneic models of lung cancer driven by KRAS G12C (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8882,
                "therapyName": "AMG 510 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19319,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 inhibited Erk phosphorylation, cell proliferation, and induced apoptosis in lung cancer cell lines harboring KRAS G12C in culture, resulted in tumor growth inhibition and regression in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19324,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring KRAS G12S did not demonstrate sensitivity to MRTX849 treatment in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1128,
                "profileName": "KRAS G12S"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19328,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and RMC-4550 combination treatment resulted in enhanced inhibition of KRAS pathway signaling in lung cancer cell lines harboring KRAS G12C in culture, and greater tumor growth inhibition in cell line xenograft models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8997,
                "therapyName": "MRTX849 + RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19330,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Gilotrif (afatinib) combination treatment synergistically inhibited proliferation of lung cancer cells harboring KRAS G12C in culture, and inhibited tumor growth in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8998,
                "therapyName": "Afatinib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19332,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Vistusertib (AZD2014) combination treatment inhibited KRAS and mTOR signaling in lung cancer cell lines harboring KRAS G12C, resulted in synergistic inhibition of cell growth in culture, and tumor regression in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8999,
                "therapyName": "MRTX849 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19334,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) synergistically inhibited viability of a lung cancer cell line harboring KRAS G12C and STK11 E317* in culture, and induced tumor regression in a cell line xenograft model (PMID: 31658955).",
            "molecularProfile": {
                "id": 34658,
                "profileName": "KRAS G12C STK11 E317*"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19335,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Ibrance (palbociclib) combination treatment resulted in enhanced inhibition of Rb1 phosphorylation and cell cycle progression in lung cancer cell lines harboring KRAS G12C and CDKN2A deletion, led to synergistic inhibition of cell growth in culture, and induced tumor regression in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 34659,
                "profileName": "CDKN2A del KRAS G12C"
            },
            "therapy": {
                "id": 9001,
                "therapyName": "MRTX849 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19354,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft lung cancer cell line harboring EGFR V769_D770insASV demonstrated sensitivity to TAS6417 in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 30999,
                "profileName": "EGFR V769_D770insASV"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19396,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited Egfr phosphorylation and cell viability, and induced apoptosis in a lung cancer patient cell line harboring EGFR N771_P772insH in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 32755,
                "profileName": "EGFR N771_P772insH"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19397,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) inhibited Egfr phosphorylation and cell viability, and induced apoptosis in a lung cancer patient cell line harboring EGFR N771_P772insH in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 32755,
                "profileName": "EGFR N771_P772insH"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19496,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with MAP3K1-deficiency via knockdown was sensitive to Selumetinib (AZD6244), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34163,
                "profileName": "MAP3K1 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19499,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with MAP2K4-deficiency via knockdown was sensitive to Selumetinib (AZD6244), demonstrating decreased cell proliferation in culture and reduced tumor volume in cell line xenograft models (PMID: 29795445).",
            "molecularProfile": {
                "id": 34164,
                "profileName": "MAP2K4 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with MAP3K1-deficiency via knockdown was sensitive to Mekinist (trametinib), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34163,
                "profileName": "MAP3K1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19505,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with MAP3K1-deficiency via knockdown was sensitive to SCH772984, demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34163,
                "profileName": "MAP3K1 dec exp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19508,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with MAP2K4-deficiency via knockdown was sensitive to Mekinist (trametinib), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34164,
                "profileName": "MAP2K4 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19511,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with MAP2K4-deficiency via knockdown was sensitive to SCH772984, demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34164,
                "profileName": "MAP2K4 dec exp"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19514,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with MAP3K1-deficiency via knockdown was sensitive to Mektovi (binimetinib), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34163,
                "profileName": "MAP3K1 dec exp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19517,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line with MAP2K4-deficiency via knockdown was sensitive to Mektovi (binimetinib), demonstrating decreased cell proliferation in culture (PMID: 29795445).",
            "molecularProfile": {
                "id": 34164,
                "profileName": "MAP2K4 dec exp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19520,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer xenograft models with wild-type MAP2K4 and MAP3K1 did not respond to treatment with Selumetinib (AZD6244) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34182,
                "profileName": "MAP2K4 wild-type MAP3K1 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, introduction of an AGK-BRAF fusion in a lung cancer cell line harboring EGFR L858R and EGFR T790M conferred resistance to Tagrisso (osimertinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34426,
                "profileName": "AGK - BRAF EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, introduction of an AGK-BRAF fusion in lung cancer cell lines harboring an EGFR exon 19 deletion conferred resistance to Tagrisso (osimertinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19693,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M and expressing an AGK-BRAF fusion was resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34426,
                "profileName": "AGK - BRAF EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19694,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M and expressing an AGK-BRAF fusion was resistant to growth inhibition by Tafinlar (dabrafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34426,
                "profileName": "AGK - BRAF EGFR T790M EGFR L858R"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19695,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines harboring an EGFR exon 19 deletion and expressing an AGK-BRAF fusion were resistant to growth inhibition by Tafinlar (dabrafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19696,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring an EGFR exon 19 deletion and expressing an AGK-BRAF fusion was resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19700,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a lung cancer patient-derived xenograft (PDX) cell line harboring an EGFR exon 19 deletion and a PJAR-BRAF fusion in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 8996,
                "therapyName": "Osimertinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19705,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Tarceva (erlotinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19706,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Tagrisso (osimertinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19707,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition by Gilotrif (afatinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19708,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Zelboraf (vemurafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19709,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition by Iressa (gefitinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19710,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by RXDX-105 (CEP-32496) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19711,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Tafinlar (dabrafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19712,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Nexavar (sorafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19713,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with LY3009120 inhibited growth and resulted in increased apoptotic signaling and decreased MEK and ERK phosphorylation in a lung cancer patient-derived xenograft (PDX) cell line harboring an EGFR exon 19 deletion and a PJAR-BRAF fusion in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19714,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with LY3009120 inhibited growth and resulted in increased apoptotic signaling in a lung cancer cell line harboring an EGFR exon 19 deletion and expressing an AGK-BRAF fusion in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19729,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OBI-999 treatment inhibited tumor growth in a Globo H-expressing lung cancer cell line xenograft model and a lung cancer patient-derived xenograft (PDX) model (Cancer Res 2019;79(13 Suppl):Abstract nr 4815).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9197,
                "therapyName": "OBI-999",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17532,
                    "pubMedId": null,
                    "title": "Novel Globo H targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/4815"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19888,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) synergistically inhibited viability of a lung cancer cell line harboring KRAS G12C and STK11 P281fs in culture, and induced tumor regression in a cell line xenograft model (PMID: 31658955).",
            "molecularProfile": {
                "id": 34655,
                "profileName": "KRAS G12C STK11 P281fs"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Ibrance (palbociclib) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C and CDK4 amplification in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34662,
                "profileName": "CDK4 amp KRAS G12C"
            },
            "therapy": {
                "id": 9001,
                "therapyName": "MRTX849 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19895,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Ibrance (palbociclib) combination treatment synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9001,
                "therapyName": "MRTX849 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19896,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19898,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Vistusertib (AZD2014) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 8999,
                "therapyName": "MRTX849 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19909,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and STK11 E317* in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34658,
                "profileName": "KRAS G12C STK11 E317*"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19911,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and STK11 E317* in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34658,
                "profileName": "KRAS G12C STK11 E317*"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19913,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and STK11 P281fs in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34655,
                "profileName": "KRAS G12C STK11 P281fs"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines demonstrated sensitivity to growth inhibition by BOS172722 in culture (PMID: 31575759).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9311,
                "therapyName": "BOS172722",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17794,
                    "pubMedId": 31575759,
                    "title": "High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575759"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20505,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NCGC00249987 did not inhibit growth, but inhibited migration and invasion in lung cancer cell lines expressing high levels of Eya2 in culture (PMID: 31285279).",
            "molecularProfile": {
                "id": 35214,
                "profileName": "EYA2 over exp"
            },
            "therapy": {
                "id": 9374,
                "therapyName": "NCGC00249987",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17869,
                    "pubMedId": 31285279,
                    "title": "Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285279"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20601,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-2852 treatment inhibited phosphorylation of Erk and Akt and proliferation of lung cancer cells harboring G12C in culture (PMID: 31332011).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9408,
                "therapyName": "BI-2852",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17956,
                    "pubMedId": 31332011,
                    "title": "Drugging an undruggable pocket on KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31332011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring SLC34A2-ROS1 was sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568).",
            "molecularProfile": {
                "id": 10084,
                "profileName": "SLC34A2 - ROS1"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20630,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived lung cancer cell line harboring EZR-ROS1 demonstrated sensitive to treatment with DS6051b in culture, demonstrating inhibition of cell growth (PMID: 31399568).",
            "molecularProfile": {
                "id": 10681,
                "profileName": "EZR - ROS1"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20632,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model with lung cancer harboring CD74-ROS1 was sensitive to DS6051b, demonstrating tumor growth inhibition (PMID: 31399568).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20650,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring SLC34A2-ROS1 and expressing ROS1 G2032R were sensitive to treatment with DS6051b, demonstrating cell growth inhibition in culture (PMID: 31399568).",
            "molecularProfile": {
                "id": 35270,
                "profileName": "SLC34A2 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20651,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring SLC34A2-ROS1 and expressing ROS1 G2032R were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating cell growth inhibition in culture (PMID: 31399568).",
            "molecularProfile": {
                "id": 35270,
                "profileName": "SLC34A2 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20653,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring SLC34A2-ROS1 and expressing ROS1 G2032R were resistant to treatment with Xalkori (crizotinib) in culture and mouse models (PMID: 31399568).",
            "molecularProfile": {
                "id": 35270,
                "profileName": "SLC34A2 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21047,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) in combination with Zykadia (ceritinib) induced tumor regression in a patient-derived xenograft (PDX) model of lung cancer overexpressing MET but with no amplification and harboring an EML4-ALK rearrangement (PMID: 30674502).",
            "molecularProfile": {
                "id": 35514,
                "profileName": "EML4 - ALK MET over exp"
            },
            "therapy": {
                "id": 9543,
                "therapyName": "Capmatinib + Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21048,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) treatment reduced viability of a lung cancer cell line harboring an ERBB2 (HER2) amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21049,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment led to tumor stasis for more than 3 weeks in a cell line xenograft model of lung cancer harboring an EGFR exon 19 deletion and a MET amplification (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21050,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment combined with Iressa (gefitinib) induced cell death of an Iressa (gefitinib)-resistant lung cancer cell line harboring an EGFR exon 19 deletion and a MET amplification in culture, and induced tumor regression in a cell line xenograft model (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 7415,
                "therapyName": "Capmatinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring an EGFR exon 19 deletion and a MET amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21093,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment combined with Tarceva (erlotinib) enhanced killing of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8282,
                "therapyName": "Capmatinib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21094,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) combined with Taxotere (docetaxel) synergistically induced killing of lung cancer cell lines harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 9547,
                "therapyName": "Capmatinib + Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21096,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of Venclexta (venetoclax) to Capmatinib (INC280) did not demonstrate synergistic killing in lung cancer cell lines harboring a MET amplification compared to Capmatinib (INC280) in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 9548,
                "therapyName": "Capmatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21097,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) combined with S63845 synergistically induced killing of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 9549,
                "therapyName": "Capmatinib + S63845",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21098,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) combined with A-1155463 synergistically induced killing of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 9550,
                "therapyName": "A-1155463 + Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Savolitinib (AZD6094) treatment inhibited proliferation of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21104,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) treatment inhibited proliferation of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21105,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) treatment inhibited proliferation of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21111,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited phosphorylation of Met, Akt and Erk, and reduced proliferation and viability of lung cancer cell lines harboring a MET amplification in culture, and induced enhanced tumor regression in a cell line xenograft model (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01014598",
            "title": "Cisplatin in Treating Patients With Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01218867",
            "title": "Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 984,
                    "therapyName": "Anti-VEGFR2 CAR CD8 lymphocytes",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01366144",
            "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01386580",
            "title": "An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 974,
                    "therapyName": "2B3-101",
                    "synonyms": null
                },
                {
                    "id": 1274,
                    "therapyName": "2B3-101 + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01470209",
            "title": "A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1314,
                    "therapyName": "Buparlisib + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01859026",
            "title": "A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1253,
                    "therapyName": "Binimetinib + Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01935336",
            "title": "Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 877,
                    "therapyName": "Ponatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01999985",
            "title": "Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1351,
                    "therapyName": "Afatinib + Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02047747",
            "title": "A Phase II Study of Dacomitinib in Progressive Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 714,
                    "therapyName": "Dacomitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02155465",
            "title": "Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1858,
                    "therapyName": "Erlotinib + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02241369",
            "title": "Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5846,
                    "therapyName": "INO-3106 + INO-9012",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02264236",
            "title": "Vaccination of Advanced-Stage Lung Cancer Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9199,
                    "therapyName": "Montanide ISA 51 + P10s-PADRE",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02310464",
            "title": "Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7271,
                    "therapyName": "OBI-821 + OBI-833",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02429843",
            "title": "A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1242,
                    "therapyName": "Carotuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02433626",
            "title": "Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6962,
                    "therapyName": "COTI-2",
                    "synonyms": null
                },
                {
                    "id": 8277,
                    "therapyName": "Cisplatin + COTI-2",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02538627",
            "title": "Phase 1 Combination Study of MM-151 and MM-121",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 820,
                    "therapyName": "Seribantumab",
                    "synonyms": null
                },
                {
                    "id": 821,
                    "therapyName": "MM-151",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02675829",
            "title": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03188965",
            "title": "First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5962,
                    "therapyName": "BAY1895344",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03199586",
            "title": "Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7358,
                    "therapyName": "NP-G2-044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03373760",
            "title": "Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03477162",
            "title": "Metformin Pharmacology in Human Cancers: A Proof of Principle Study",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03597009",
            "title": "A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5080,
                    "therapyName": "Nivolumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03719768",
            "title": "Avelumab With Radiotherapy in Patients With Leptomeningeal Disease",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04085315",
            "title": "Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8722,
                    "therapyName": "Alisertib + Osimertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04148937",
            "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8894,
                    "therapyName": "LY3475070",
                    "synonyms": null
                },
                {
                    "id": 8895,
                    "therapyName": "LY3475070 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04259450",
            "title": "Study to Assess AFM24 in Advanced Solid Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5856,
                    "therapyName": "AFM24",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04273061",
            "title": "Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04287868",
            "title": "Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9432,
                    "therapyName": "M7824 + NHS-IL12 + PDS0101",
                    "synonyms": null
                }
            ]
        }
    ]
}